S-8 1 tm2113838d1_s8.htm FORM S-8

 

As filed with the Securities and Exchange Commission on April 26, 2021

Registration No. 333-         

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

MIND MEDICINE (MINDMED) INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada

(State or other jurisdiction of

incorporation or organization)

 

98-1582438

(I.R.S. Employer

Identification No.)

 

One World Trade Center

Suite 8500

New York, New York

(Address of Principal Executive Offices)

 

 

10007

(Zip Code)

 

MIND MEDICINE (MINDMED) INC. STOCK OPTION PLAN

MIND MEDICINE (MINDMED) INC. PERFORMANCE AND RESTRICTED SHARE UNIT PLAN

(Full title of the plans)

 

C T Corporation System

1015 15th Street N.W., Suite 1000

Washington, D.C., 20005

(Name and address of agent for service)

 

(202) 572-3111

(Telephone number, including area code, of agent for service)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ¨ Accelerated filer  ¨
Non-accelerated filer    x                Smaller reporting company  ¨
  Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

CALCULATION OF REGISTRATION FEE*

 

Title of securities

to be registered1

 

Amount to be registered2

 

Proposed maximum offering price per share

 

Proposed

maximum aggregate offering price 5

 

Amount of registration fee

Subordinate Voting Shares subject to outstanding options 18,195,750 shares $0.57923 $10,538,978 $1,150
Subordinate Voting Shares subject to outstanding Restricted Stock Units 500,000 shares $2.1554 $1,077,500 $118

Subordinate Voting Shares not subject to outstanding awards under the Plans

 

22,036,467 shares

$2.1554

 

$47,488,586 $5,181
Total 40,732,217 shares $59,105,064 $6,449

 

1 Subordinate Voting Shares offered by Mind Medicine (MindMed) Inc. pursuant to the Mind Medicine (MindMed) Inc. Stock Option Plan (the “Stock Option Plan”) and the Mind Medicine (MindMed) Inc. Performance and Restricted Unit Share Plan (the “PR Plan,” and together with the Stock Option Plan and the PR Plan, the “Plans”).

 

2 Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an indeterminate number of additional Subordinate Voting Shares that may be offered and issued to prevent dilution resulting from share dividends, share splits, reverse share splits, combinations of shares, spin-offs, recapitalizations, mergers or similar capital adjustments as provided in the Plans.

 

3 Based on weighted average exercise price of US$0.5792 (Cdn$0.724) of options granted under the Stock Option Plan outstanding as of April 22, 2021, which was converted into U.S. dollars based on the average exchange rate on April 22, 2021, as reported by the Bank of Canada, for the conversion of Canadian dollars into U.S. dollars of Cdn$1.00 equals US$0.80

 

4 Calculated in accordance with Rule 457(c) and (h) under the Securities Act based on the average of the high and low prices for Mind Medicine (Mind Med) Inc. Subordinate Voting Shares reported on the OTCQB on April 22, 2021, which was $2.155 per share.

 

5 Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the United States Securities Act of 1933, as amended (the “Securities Act”).

 

 

 

 

 

 

Part I — Information Required in the Section 10(a) Prospectus

 

Item 1.Plan Information. *

 

Item 2.Registrant Information and Employee Plan Annual Information.*

 

*The documents containing the information specified in “Item 1. Plan Information” and “Item 2. Registrant Information and Employee Plan Annual Information” of Form S-8 will be sent or given to participants, as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be, and are not, filed with the United States Securities and Exchange Commission (the “Commission”) either as part of this registration statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this registration statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

 

Part II — Information Required in the Registration Statement

 

Item 3.Incorporation of Documents by Reference.

 

The following documents filed by Mind Medicine (MindMed) Inc. (the “Company”) with the Commission are incorporated herein by reference:

 

(a)The Company’s effective registration statement on Form F-10 (File No. 333-254859) filed with the Commission on March 30, 2021, and amended April 9, 2021, which contains audited financial statements for the Registrant’s latest fiscal year.

 

(b)All documents filed by the Registrant pursuant to Section 13(a)or 15(d) of the Exchange Act subsequent to the date of this registration statement and prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof commencing on the respective dates on which such documents are filed.

 

Item 4.Description of Securities.

 

Not applicable.

 

Item 5.Interests of Named Experts and Counsel.

 

Not applicable.

 

Item 6.Indemnification of Directors and Officers.

 

The Corporation is subject to the provisions of Part 5, Division 5 of the Business Corporations Act (British Columbia) (the “Act”).

 

Under Section 160 of the Act, the Corporation may, subject to Section 163 of the Act:

 

  (a) indemnify an individual who:

 

1

 

 

  (i) is or was a director or officer of the Corporation,

 

  (ii) is or was a director or officer of another corporation (A) at a time when such corporation is or was an affiliate of the Corporation; or (B) at the Corporation’s request, or

 

  (iii) at the Corporation’s request, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity,

 

including, subject to certain limited exceptions, the heirs and personal or other legal representatives of that individual (collectively, an “eligible party”), against all eligible penalties, defined below, to which the eligible party is or may be liable; and

 

  (b) after final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, where:

 

  (i) “eligible penalty” means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding,

 

  (ii) “eligible proceeding” means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Corporation or an associated corporation (A) is or may be joined as a party, or (B) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding,

 

  (iii) “expenses” includes costs, charges and expenses, including legal and other fees, but does not include judgments, penalties, fines or amounts paid in settlement of a proceeding, and

 

  (iv) “proceeding” includes any legal proceeding or investigative action, whether current, threatened, pending or completed.

 

Under Section 161 of the Act, and subject to Section 163 of the Act, the Corporation must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding if the eligible party (a) has not been reimbursed for those expenses, and (b) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding.

Under Section 162 of the Act, and subject to Section 163 of the Act, the Corporation may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of the proceeding, provided that the Corporation must not make such payments unless the Corporation first receive from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited under Section 163 of the Act, the eligible party will repay the amounts advanced.

 

Under Section 163 of the Act, the Corporation must not indemnify an eligible party against eligible penalties to which the eligible party is or may be liable or pay the expenses of an eligible party in respect of that proceeding under Sections 160, 161 or 162 of the Act, as the case may be, if any of the following circumstances apply:

 

2

 

 

  (a)

if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, the Corporation was prohibited from giving the indemnity or paying the expenses by the Corporation’s memorandum or articles;

 

  (b) if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, the Corporation is prohibited from giving the indemnity or paying the expenses by the Corporation’s memorandum or articles;

 

  (c) if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of the Corporation or the associated corporation, as the case may be; or

 

  (d) in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party’s conduct in respect of which the proceeding was brought was lawful.

 

If an eligible proceeding is brought against an eligible party by or on behalf of the Corporation or by or on behalf of an associated corporation, the Corporation must not either indemnify the eligible party under Section 160(a) of the Act against eligible penalties to which the eligible party is or may be liable, or pay the expenses of the eligible party under Sections 160(b), 161 or 162 of the Act, as the case may be, in respect of the proceeding.

 

Under Section 164 of the Act, and despite any other provision of Part 5, Division 5 of the Act and whether or not payment of expenses or indemnification has been sought, authorized or declined under Part 5, Division 5 of the Act, on application of the Corporation or an eligible party, the court may do one or more of the following:

 

  (a) order the Corporation to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding;

 

  (b) order the Corporation to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding;

 

  (c) order the enforcement of, or any payment under, an agreement of indemnification entered into by the Corporation;

 

  (d) order the Corporation to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under Section 164 of the Act; or

 

  (e) make any other order the court considers appropriate.

 

Section 165 of the Act provides that the Corporation may purchase and maintain insurance for the benefit of an eligible party or the heirs and personal or other legal representatives of the eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Corporation or an associated corporation.

 

Under the Corporation’s articles, and subject to the Act, the Corporation must indemnify a director, former director or alternate director and his or her heirs and legal personal representatives against all eligible penalties to which such person is or may be liable, and the Corporation must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each director and alternate director is deemed to have contracted with the Corporation on the terms of the indemnity contained in the Corporation’s articles.

 

3

 

 

Under the Corporation’s articles, and subject to the Act, the Corporation may agree to indemnify and may indemnify any person (including an eligible party). The Corporation has entered into indemnity agreements with certain of the Corporation’s directors and officers.

 

Pursuant to the Corporation’s articles, the failure of an eligible party to comply with the Act or the Corporation’s articles, or, if applicable, any former Companies Act or former articles of the Corporation, does not invalidate any indemnity to which he or she is entitled under the Corporation’s articles.

 

Under the Corporation’s articles, the Corporation may purchase and maintain insurance for the benefit of any person (or his or her heirs or legal personal representatives) who:

 

  · is or was a director, alternate director, officer, employee or agent of the Corporation

 

  · is or was a director, alternate director, officer, employee or agent of another corporation at a time when such corporation is or was an affiliate of the Corporation;
     
  · at the Corporation’s request, is or was, a director, alternate director, officer, employee or agent of a corporation or of a partnership, trust, joint venture or other unincorporated entity;

 

  · at the Corporation’s request, is or was, or holds or held a position equivalent to that of, a director, alternate director or officer of a partnership, trust, joint venture or other unincorporated entity,

 

against any liability incurred by him or her as a director, alternate director, officer, employee or agent or person who holds or held such equivalent position.

 

The Corporation maintains directors' and officers' liability insurance which insures directors and officers for losses as a result of claims against the directors and officers of the Registrant in their capacity as directors and officers.

 

Item 7.Exemption from Registration Claimed.

 

Not applicable.

 

Item 8.Exhibits.

 

An Exhibit Index appears on page 6 hereof and is incorporated herein by reference.

 

Item 9.Undertakings.

 

(a)       The undersigned registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

4

 

 

(i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in the volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

(iii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

 

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(b)       The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(h)        Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

5

 

 

EXHIBIT INDEX

 

Exhibit
No.
  Description
4.1  Amended and Restated Articles of Mind Medicine (MindMed) Inc.
4.2  Mind Medicine (MindMed) Inc. Stock Option Plan.
4.3  Mind Medicine (MindMed) Inc. Performance and Restricted Share Unit Plan.
5.1  Opinion of Cassels Brock & Blackwell LLP
23.1  Consent of Cassels Brock & Blackwell (contained in Exhibit 5.1 hereto).
23.2  Consent of RSM Canada LLP.
24.1  Powers of Attorney (included on the signature page of this registration statement).

 

6

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vancouver, Province of British Columbia, on April 23, 2021.

 

  MIND MEDICINE (MINDMED) INC.
   
  By: /s/ Jamon Alexander (“JR”) Rahn
    Name: Jamon Alexander (“JR”) Rahn
    Title: Chief Executive Officer

 

7

 

 

POWERS OF ATTORNEY

AND

SIGNATURES

 

Each person whose signature appears below constitutes and appoints Jamon Alexander (“JR”) Rahn and David Guebert, or either of them, his or her true and lawful attorneys-in-fact and agents, each of whom may act alone, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments to this Registration Statement, including post-effective amendments to this Registration Statement, and any related registration statements necessary to register additional securities, and to file the same, with all exhibits thereto, and other documents and in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all his or her said attorneys-in-fact and agents or any of them or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

 

This Power of Attorney may be executed in multiple counterparts, each of which shall be deemed an original, but which taken together shall constitute one instrument.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

8

 

 

Signature   Title   Date
         
/s/ Jamon Alexander (“JR”) Rahn   Chief Executive Officer and Director   April 23, 2021
Jamon Alexander (“JR”) Rahn   (principal executive officer)    
         
/s/ David D. Guebert   Chief Financial Officer   April 23, 2021
David D. Guebert   (principal financial and accounting officer)    
         
/s/ Miri Halperin Wernli   Executive President and Director   April 23, 2021
Dr. Miri Halperin Wernli        
         
/s/ Perry Dellelce   Director   April 25, 2021
Perry Dellelce        
         
/s/ Stephen L. Hurst   Director   April 23, 2021
Stephen L. Hurst        
         
/s/ Bruce Linton   Director   April 23, 2021
Bruce Linton        
         
/s/Brigid Makes   Director   April 23, 2021
Brigid Makes        

 

9